FOXF1 is required for the oncogenic properties of PAX3-FOXO1 in rhabdomyosarcoma
pubmed.ncbi.nlm.nih.gov shows its articles on its own site.
Read the article on pubmed.ncbi.nlm.nih.gov ↗Article · Feb 2021 · 1 min read
In brief
In brief
This study identifies FOXF1 as a critical downstream target of the PAX3-FOXO1 fusion oncogene in fusion-positive rhabdomyosarcoma. CRISPR-mediated FOXF1 inactivation suppresses tumor growth and induces myogenic differentiation, revealing FOXF1 as a potential therapeutic target for this aggressive pediatric soft tissue malignancy.
Written by the GCMD Library team from the article.
Statements in this article
PAX3-FOXO1 fusion protein is the key oncogenic driver in fusion positive rhabdomyosarcoma (FP-RMS), an aggressive soft tissue malignancy with a particularly poor prognosis.
FOXF1 transcription factor is uniquely expressed in FP-RMS and is required for FP-RMS tumorigenesis.
PAX3-FOXO1 directly binds to FOXF1 enhancers and induces FOXF1 gene expression.
CRISPR/Cas9 mediated inactivation of either FOXF1 coding sequence or FOXF1 enhancers suppresses FP-RMS tumorigenesis even in the presence of PAX3-FOXO1 oncogene.
Knockdown or genetic knockout of FOXF1 induces myogenic differentiation in PAX3-FOXO1-positive FP-RMS.
Over-expression of FOXF1 decreases myogenic differentiation in primary human myoblasts.
In FP-RMS tumor cells, FOXF1 protein binds chromatin near enhancers associated with FP-RMS gene signature.
FOXF1 cooperates with PAX3-FOXO1 and E-box transcription factors MYOD1 and MYOG to regulate FP-RMS-specific gene expression.
FOXF1 functions downstream of PAX3-FOXO1 to promote FP-RMS tumorigenesis.